Pharmacologically active CNS compounds
AssigneeGlaxo Wellcome Inc.
InventorsAlistair A. Miller, Malcolm S. Nobbs, Richard M. Hyde, Michael J. Leach
Life of this patent
Estimating the term…
Abstract
A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
Claims12
4-Amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine and pharmaceutically acceptable acid addition salts thereof.
4-Amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine methanesulphonate.
A pharmaceutical formulation comprising a pharmaceutically effective amount of 4-amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carriers therefor.
Dependencies are inferred from the claim text.